Bionyra brings in $165M for next-generation immune drugs

Bionyra Launches with $165M and Three Immune Disease Biologics

Bionyra, a biotechnology company co-founded by Sofinnova Partners and Frédéric Marrache, has emerged from stealth with $165 million in Series A funding. The company is rapidly advancing three licensed biologics into clinical testing for immune diseases such as inflammatory bowel disease (IBD) and atopic dermatitis. Two of its assets, BYN-002 (a monoclonal antibody targeting TL1A) and BYN-003 (a bispecific antibody targeting TL1A and IL-23), are already in Phase 1 studies. The third asset, BYN-001 (an anti-IL-25 monoclonal antibody), is planned for atopic dermatitis and other inflammatory conditions, with a potential quarterly or twice-yearly injection schedule. The funding round was co-led by Sofinnova and Jeito Capital.

• Bionyra secured $165 million in Series A funding, co-led by Sofinnova Partners and Jeito Capital, with additional investors including Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures. This substantial investment supports the company's strategy of licensing three advanced biologic assets from China and U.S.-based companies, enabling a rapid entry into clinical development for immune conditions.
• The company's pipeline includes BYN-002, a monoclonal antibody targeting TL1A with an extended half-life, and BYN-003, a bispecific antibody combining TL1A with an IL-23 subtype, both currently in Phase 1 studies for inflammatory bowel disease. A third asset, BYN-001, an anti-IL-25 monoclonal antibody, is slated for development in atopic dermatitis and other inflammatory conditions, with a focus on convenient dosing.
• Bionyra aims to develop "next-generation biologics" that can potentially overcome the limitations of existing immune disease treatments, such as partial response rates or safety concerns (e.g., JAK inhibitors' black box warnings). By targeting novel or combined pathways like TL1A, IL-23, and IL-25, the company seeks to offer more effective and patient-friendly therapeutic options, leveraging the agility of the biotech space for accelerated development.

The Persistent Challenges in Inflammatory Bowel Disease Treatment

Despite significant therapeutic advances over the past two decades, IBD management continues to face substantial unresolved challenges across both conventional and precision medicine paradigms. A considerable proportion of patients fail to achieve durable clinical remission, underscoring a persistent unmet need for more effective, better-tolerated, and individually tailored treatment strategies.

• Limited efficacy and toxicity of conventional therapies: Anti-inflammatories, glucocorticoids, and immunosuppressants are constrained by systemic adverse effects and cumulative toxicity during long-term use. Systemic corticosteroids are ineffective for maintaining remission in ulcerative colitis, and prolonged use carries significant safety liabilities.

• Primary and secondary treatment failure with biologics: Anti-TNF agents such as infliximab and adalimumab, despite considerable clinical success, are limited by primary non-response and secondary loss of response — frequently driven by the development of anti-drug antibodies. Current treatments for UC, including aminosalicylates, biologics, and immunomodulators, are further limited by drug resistance and significant adverse effects.

• Risks and health-economic burden of modern precision therapies: Biologics and small-molecule drugs carry risks of severe opportunistic infections and impose an increasingly heavy health-economic burden, complicating their long-term use at a population level.

• Disease heterogeneity and patient stratification: IBD is a highly heterogeneous condition in which patients differ widely in disease phenotype, progression trajectory, and response to specific therapies. The significance of biomarkers can be difficult to interpret on an individual basis, making early identification of patients requiring more intensive treatment particularly challenging.

• Gaps in precision medicine implementation: Despite progress in developing prognostic tools and biomarker-driven stratification frameworks, clinical trials have not routinely incorporated these approaches into their study design. Widespread implementation of personalized treatment strategies remains limited, underscoring the need for further research to integrate precision medicine into routine IBD care.

• Emerging therapeutic modalities face their own barriers: RNA interference (RNAi)-based approaches — while mechanistically promising — face obstacles including in vivo RNA degradation by endogenous ribonucleases and pH variation, unintended off-target effects, and immunostimulation, limiting their clinical translation without advanced delivery systems.

Bionyra's Novel Targets: TL1A, IL-23, and IL-25 in Immune Diseases

Recent research has substantially expanded the target landscape for inflammatory bowel disease (IBD), moving well beyond established anti-TNF pathways. Among the most clinically advanced are IL-23p19 inhibitors — including risankizumab, mirikizumab, and guselkumab — which have demonstrated high efficacy and durable responses in landmark phase 3 trials across both Crohn's disease (CD) and ulcerative colitis (UC). The SEQUENCE trial notably established the superiority of risankizumab over ustekinumab in achieving endoscopic and clinical endpoints in CD, underscoring the therapeutic value of selective p19 subunit blockade over prior p40 inhibition. Beyond IL-23, additional cytokine targets under active investigation include IL-36, IL-17C, and SMAD7, alongside TL1A and complement components. The development of bi- and polyspecific monoclonal antibodies capable of simultaneously interfering with multiple pathological pathways represents a particularly promising strategic direction. Genomic approaches have further enriched the target space: genome-wide association meta-analyses of over 63,000 IBD cases identified 90 previously unknown risk loci and 506 high-confidence risk genes — 384 of which were not previously reported — converging on immune regulation and microbial interaction pathways. Notably, 46 of these risk genes are already targeted by 225 approved or late-stage investigational drugs.

At the molecular level, two specific targets have garnered considerable attention. TNFSF11 (RANKL), expressed selectively in the terminal ileum — the primary site of CD pathology — has been identified through network analyses as linked to mast cells in the ileal mucosa, suggesting that RANKL blockade via denosumab could attenuate localized inflammatory cascades with reduced systemic toxicity. Separately, the β2 integrin Mac-1 (αMβ2) has emerged as a tractable target, with the natural polymethoxyflavone tangeretin demonstrating direct binding at a dissociation constant of 3.87 μM, blocking its interaction with ICAM-1 and suppressing the downstream Vav1/Rac1 signaling pathway, thereby inhibiting macrophage recruitment in preclinical colitis models. Novel drug delivery platforms are also advancing in parallel; the MXene/CBN@GelMA (MCG) nanozyme composite system integrates antioxidative MXene nanosheets and anti-inflammatory columbianadin within a gelatin methacryloyl hydrogel, scavenging reactive oxygen species via a superoxide dismutase–catalase cascade and demonstrating mucosal preservation in dextran sulfate sodium–induced IBD models.

Emerging therapeutic paradigms are also targeting the microbiome-metabolic axis, with strategies including fecal microbiota transplantation, probiotic and bacteriophage therapies, helminth-based approaches, and precision genome editing of the gut microbiome — all aimed at restoring homeostasis across short-chain fatty acid, bile acid, and redox pathways. These approaches are increasingly being integrated within precision medicine frameworks that leverage multi-omics platforms — encompassing genomics, transcriptomics, microbiome profiling, and metabolomics — alongside AI-driven tools for patient stratification and treatment response prediction. Therapeutic drug monitoring (TDM)-guided optimization further complements this landscape by enhancing biologic efficacy and mitigating immunogenicity, while rational combination strategies targeting complementary pathways offer a path toward more durable remission.

Bionyra's Ambitious Entry into Inflammatory Disease Biologics

The emergence of Bionyra with significant funding and a pipeline focused on novel biologics for immune diseases signals a dynamic shift in how the pharmaceutical industry is approaching complex inflammatory conditions. At the heart of Bionyra's strategy are two assets targeting the TL1A pathway, a cytokine-receptor system increasingly recognized for its pivotal role in driving inflammation and fibrosis across a spectrum of autoimmune disorders, particularly inflammatory bowel disease (IBD). Recent clinical trials with other anti-TL1A antibodies have shown promising results in ulcerative colitis, validating this target and setting a high bar for new entrants.

Bionyra's approach with both a traditional monoclonal antibody (BYN-002) and a bispecific antibody (BYN-003) that also targets IL-23 is particularly intriguing. This bispecific design could offer a significant advantage by simultaneously modulating two key inflammatory drivers, potentially leading to more robust and sustained clinical responses. This multi-pronged attack on inflammation could be crucial in patient populations who do not respond adequately to single-target therapies. Furthermore, the company's diversification into atopic dermatitis with an anti-IL-25 monoclonal antibody (BYN-001) demonstrates a strategic breadth, addressing another high-unmet-need area with a distinct mechanism of action.

However, the path forward is not without its challenges. The literature highlights a notable risk of immunogenicity with anti-TL1A therapies, where patients can develop anti-drug antibodies that may reduce drug efficacy. Bionyra will need to demonstrate a favorable immunogenicity profile or develop strategies to mitigate this risk. Moreover, the competitive landscape for TL1A inhibitors is rapidly evolving, with several other agents already in advanced clinical development. Bionyra's success will hinge on its ability to differentiate its assets through superior efficacy, safety, or by identifying specific patient populations most likely to benefit, potentially through companion diagnostics. The complexity of the TL1A/DR3 pathway itself, with its varied roles and interactions, also underscores the need for deep mechanistic understanding to optimize therapeutic outcomes.